Physician profile
Agata E Draper
NPI 1265909709
$12,071.15
in general payments reported to CMS, 2019-2025
27 companies · $3,395 in 2025
The $3,395 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $538 · 2022: $2,780 · 2023: $2,264 · 2024: $3,093 · 2025: $3,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,294 · Education: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,293.77 |
| Education | $459.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,448.99 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,271.79 | 2021-2025 | |
| Lilly USA, LLC | $1,115.74 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Allergan, INC. | $1,067.77 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $931.41 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $753.90 | 2022-2025 | Winlevi, Ilumya, Absorica Ld |
| Leo Pharma INC. | $693.27 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $682.06 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $551.70 | 2022-2025 | |
| Ucb, INC. | $470.41 | 2022-2025 | Bimzelx |
| Pfizer INC. | $425.71 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $344.17 | 2024-2025 | Zoryve |
| Organon LLC | $320.80 | 2025 | Vtama |
| Epi Health, LLC | $300.61 | 2021-2022 | |
| Amgen INC. | $206.97 | 2023-2025 | Otezla, Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $203.74 | 2023-2025 | |
| Incyte Corporation | $202.25 | 2021-2025 | Opzelura |
| Genzyme Corporation | $199.93 | 2021-2024 | |
| Journey Medical Corporation | $195.95 | 2022-2025 | |
| Dermavant Sciences, INC. | $195.11 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $178.29 | 2023-2025 | Nemluvio, Epsolay, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $159.60 | 2022-2025 | Cabtreo, Jublia, Duobrii |
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Botanix Sb INC | $35.97 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $30.88 | 2024 | Ycanth |
| Organogenesis INC. | $17.59 | 2025 | Nushield |
| Almirall LLC | $13.54 | 2023 | Seysara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agata Draper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.